Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T-lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia.

Bourgeois, Wallace; Yang, Edward; Chiarle, Roberto; Burns, Melissa

Bourgeois, Wallace; Yang, Edward; Chiarle, Roberto; Burns, Melissa.

Afiliação

Bourgeois W; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
Yang E; Department of Radiology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Chiarle R; Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Burns M; Division of Haematopathology, European Institute of Oncology IRCCS, Milan, Italy.

Pediatr Blood Cancer ; 71(6): e30978, 2024 Jun.

Article em En | MEDLINE | ID: mdl-38532250

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Pediatr Blood Cancer Assunto da revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google